-
Artigo de Revisão09/06/2025
Prophylactic internal iliac artery balloon occlusion in the management of placenta accreta spectrum disorders: a meta-analysis
- Nicole dos Santos Pimenta
, - Ana Clara Felix de Farias Santos ,
- Maírla Marina Ferreira Dias ,
- Gabriela Oliveira Gonçalves Molino ,
- Ana Gabriela Alves Pereira , [ ... ],
- Pedro Henrique Costa Matos da Silva
Resumo
Artigo de RevisãoProphylactic internal iliac artery balloon occlusion in the management of placenta accreta spectrum disorders: a meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo19
- Nicole dos Santos Pimenta ,
- Ana Clara Felix de Farias Santos ,
- Maírla Marina Ferreira Dias ,
- Gabriela Oliveira Gonçalves Molino ,
- Ana Gabriela Alves Pereira ,
- Pedro Henrique Costa Matos da Silva
Visualizações93Ver maisAbstract
Objective:
Placenta accreta spectrum (PAS) describes the failure of placental detachment. PAS is a pregnancy-associated life-threatening condition which increases hemorrhage risk. We evaluated safety and efficacy of internal iliac artery balloon occlusion (IIABOC) on bleeding volume among pregnant women with diagnosis or suspicion of PAS.
Data source:
We searched PubMed, Embase and Cochrane databases.
Study selection:
Randomized controlled trials (RCTs) and observational studies comparing the efficacy of preoperative prophylactic balloon catheters to a control group with standard care in patients with a prenatal screening of PAS.
Data collect:
We computed odds ratio (OR) for binary endpoints and mean difference (MD) for continuous endpoints, with 95% confidence intervals (CIs). We performed random effects models and assessed I2 heterogeneity statistics.
Data synthesis:
Twenty-four studies were included, of whom 1,023 (51%) received balloons and 983 (49%) did not undergo balloon management. Patients receiving IIABOC had a greater decrease in estimated blood loss (MD −0.33; 95% CI −0.55, 0.11) and increase in operation time (MD 17.21; 95% CI 3.43, 30.99). Apgar score at fifth minute (MD −0.22; 95% CI −0.36,−0.07) significantly decreased. There were no significant differences between groups regarding hysterectomy rates (OR 1.35; 95% CI 0.88, 2.09) and maternal intensive care unit admission (OR 0.81; 95% CI 0.51,1.29).
Conclusion:
While IIABOC have demonstrated a significant reduction in estimated blood loss, these findings have not been consistently replicated in RCTs and the surgeon's level of experience must be taken into account since it biases the analysis.
Visualizações93
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Resumo
Artigo de RevisãoProphylactic internal iliac artery balloon occlusion in the management of placenta accreta spectrum disorders: a meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo19
- Nicole dos Santos Pimenta ,
- Ana Clara Felix de Farias Santos ,
- Maírla Marina Ferreira Dias ,
- Gabriela Oliveira Gonçalves Molino ,
- Ana Gabriela Alves Pereira ,
- Pedro Henrique Costa Matos da Silva
Visualizações93Ver maisAbstract
Objective:
Placenta accreta spectrum (PAS) describes the failure of placental detachment. PAS is a pregnancy-associated life-threatening condition which increases hemorrhage risk. We evaluated safety and efficacy of internal iliac artery balloon occlusion (IIABOC) on bleeding volume among pregnant women with diagnosis or suspicion of PAS.
Data source:
We searched PubMed, Embase and Cochrane databases.
Study selection:
Randomized controlled trials (RCTs) and observational studies comparing the efficacy of preoperative prophylactic balloon catheters to a control group with standard care in patients with a prenatal screening of PAS.
Data collect:
We computed odds ratio (OR) for binary endpoints and mean difference (MD) for continuous endpoints, with 95% confidence intervals (CIs). We performed random effects models and assessed I2 heterogeneity statistics.
Data synthesis:
Twenty-four studies were included, of whom 1,023 (51%) received balloons and 983 (49%) did not undergo balloon management. Patients receiving IIABOC had a greater decrease in estimated blood loss (MD −0.33; 95% CI −0.55, 0.11) and increase in operation time (MD 17.21; 95% CI 3.43, 30.99). Apgar score at fifth minute (MD −0.22; 95% CI −0.36,−0.07) significantly decreased. There were no significant differences between groups regarding hysterectomy rates (OR 1.35; 95% CI 0.88, 2.09) and maternal intensive care unit admission (OR 0.81; 95% CI 0.51,1.29).
Conclusion:
While IIABOC have demonstrated a significant reduction in estimated blood loss, these findings have not been consistently replicated in RCTs and the surgeon's level of experience must be taken into account since it biases the analysis.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Nicole dos Santos Pimenta
-
Artigo de Revisão30/04/2025
Efficacy of tranexamic acid application in gynecology and obstetrics procedures: a umbrella review of systematic reviews of randomized trials
- Nicole Cristina Lottermann ,
- Nathalia Luiza Andreazza ,
- Matheus de Araújo Moura Cavalcante ,
- Laura Andrade Fernandez ,
- Carla Vitola Gonçalvez , [ ... ],
- Linjie Zhang
Resumo
Artigo de RevisãoEfficacy of tranexamic acid application in gynecology and obstetrics procedures: a umbrella review of systematic reviews of randomized trials
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo18
- Nicole Cristina Lottermann ,
- Nathalia Luiza Andreazza ,
- Matheus de Araújo Moura Cavalcante ,
- Laura Andrade Fernandez ,
- Carla Vitola Gonçalvez ,
- Linjie Zhang
Visualizações186Abstract
Objective:
This umbrella review aimed to synthesize evidence from systematic reviews of clinical trials on the efficacy of tranexamic acid in gynecology and obstetrics procedures.
Methods:
We searched Medline, Embase, SciELO and Cochrane Database of Systematic Reviews on March 11, 2024, using the term "tranexamic acid". Four reviewers independently select studies and extract data. We assessed the quality of systematic review and the quality of evidence, using AMSTAR 2 and GRADE tools, respectively.
Results:
Of 651 systematic reviews identified, 16 reviews with 96663 patients were included. The surgical procedures were cesarean section, myomectomy, hysterectomy, and cervical intraepithelial neoplasia surgery. All reviews showed a statistically significant and clinically relevant reduction in intraoperative and post-procedure blood loss, associated with intravenous or topical use of tranexamic acid. Tranexamic acid resulted in a significant reduction in the need for blood transfusions and a less pronounced drop in postoperative hematocrit and hemoglobin levels in cesarean section. Several reviews addressed the same question, but the number of included trials varied substantially, which might indicate flaws in search and selection of studies of these reviews. The quality of systematic reviews was low or critically low, and the quality of evidence was moderate.
Conclusions:
This umbrella review shows that tranexamic acid can reduce blood loss and hemorrhage in gynecology and obstetrics procedures. High quality systematic reviews are still needed.
Palavras-chave: Blood transfusionCesarean sectionEfficacyGynecologic surgical procedureshematocritHemorrhageHysterectomyObstetric surgical proceduresTranexamic acidUterine cervical dysplasiauterine myomectomyVer maisVisualizações186This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Resumo
Artigo de RevisãoEfficacy of tranexamic acid application in gynecology and obstetrics procedures: a umbrella review of systematic reviews of randomized trials
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo18
- Nicole Cristina Lottermann ,
- Nathalia Luiza Andreazza ,
- Matheus de Araújo Moura Cavalcante ,
- Laura Andrade Fernandez ,
- Carla Vitola Gonçalvez ,
- Linjie Zhang
Visualizações186Abstract
Objective:
This umbrella review aimed to synthesize evidence from systematic reviews of clinical trials on the efficacy of tranexamic acid in gynecology and obstetrics procedures.
Methods:
We searched Medline, Embase, SciELO and Cochrane Database of Systematic Reviews on March 11, 2024, using the term "tranexamic acid". Four reviewers independently select studies and extract data. We assessed the quality of systematic review and the quality of evidence, using AMSTAR 2 and GRADE tools, respectively.
Results:
Of 651 systematic reviews identified, 16 reviews with 96663 patients were included. The surgical procedures were cesarean section, myomectomy, hysterectomy, and cervical intraepithelial neoplasia surgery. All reviews showed a statistically significant and clinically relevant reduction in intraoperative and post-procedure blood loss, associated with intravenous or topical use of tranexamic acid. Tranexamic acid resulted in a significant reduction in the need for blood transfusions and a less pronounced drop in postoperative hematocrit and hemoglobin levels in cesarean section. Several reviews addressed the same question, but the number of included trials varied substantially, which might indicate flaws in search and selection of studies of these reviews. The quality of systematic reviews was low or critically low, and the quality of evidence was moderate.
Conclusions:
This umbrella review shows that tranexamic acid can reduce blood loss and hemorrhage in gynecology and obstetrics procedures. High quality systematic reviews are still needed.
Palavras-chave: Blood transfusionCesarean sectionEfficacyGynecologic surgical procedureshematocritHemorrhageHysterectomyObstetric surgical proceduresTranexamic acidUterine cervical dysplasiauterine myomectomyVer maisThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
- Nicole Cristina Lottermann
-
Artigo de Revisão30/04/2025
Letrozole and clomiphene versus letrozole alone for ovulation induction in women with PCOS: a systematic review and meta-analysis
- Karine Eskandar ,
- Juliana Almeida Oliveira ,
- Sandro Augusto Ribeiro ,
- Matheus Pedrotti Chavez ,
- Ana Isabela de Araujo Zotti , [ ... ],
- Andrea Mora de Marco Novellino
Resumo
Artigo de RevisãoLetrozole and clomiphene versus letrozole alone for ovulation induction in women with PCOS: a systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo21
- Karine Eskandar ,
- Juliana Almeida Oliveira ,
- Sandro Augusto Ribeiro ,
- Matheus Pedrotti Chavez ,
- Ana Isabela de Araujo Zotti ,
- Yasmin Jardim Meirelles Dias ,
- Andrea Mora de Marco Novellino
Visualizações232Abstract
Objective:
We aimed to compare the efficacy and safety of letrozole and clomiphene versus letrozole alone for ovulation induction in patients with Polycystic Ovary Syndrome (PCOS).
Data Sources:
We systematically searched EMBASE, PubMed, and Cochrane databases on October 31, 2024.
Study selection:
We included studies of women with PCOS treated with a combination of clomiphene and letrozole or letrozole alone to induce ovulation that reported any of the outcomes of interest, namely rate of mature follicles and ovulation, ovulation, pregnancy, miscarriages, endometrial thickness, and number of mature follicles.
Data collection:
We pooled odds ratios (OR) and mean difference (MD) with 95% confidence intervals (CI) using a random effects model using R statistical software, version 4.2.1. Heterogeneity was assessed with I statistics, and a random effects model was used.
Data Synthesis:
Four RCTs and two observational studies comprising 592 patients were included. Combined therapy was associated with a higher rate of a mature follicle (OR 2.74; 95% CI 1.72-4.37; p< 0.001; I=0%) and ovulation (OR 2.55; 95% CI 1.57-4.12; p< 0.001; I=35.9%). The number of mature follicles, number of pregnancies, thickness of endometrial lining, and the incidence of adverse events, including headache, abdominal bloating, fatigue, back pain, breast discomfort, and night sweats, were similar between groups.
Conclusion:
In women with anovulatory infertility secondary to PCOS, letrozole and clomiphene citrate combined therapy was associated with improved mature follicle and ovulation rates, with a similar safety profile compared to letrozole alone. However, no significant impact was observed on pregnancy rates.
Palavras-chave: ClomipheneInfertility, femaleLetrozoleOvulationOvulation InductionPolycystic ovary syndromeVer maisVisualizações232This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Resumo
Artigo de RevisãoLetrozole and clomiphene versus letrozole alone for ovulation induction in women with PCOS: a systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo21
- Karine Eskandar ,
- Juliana Almeida Oliveira ,
- Sandro Augusto Ribeiro ,
- Matheus Pedrotti Chavez ,
- Ana Isabela de Araujo Zotti ,
- Yasmin Jardim Meirelles Dias ,
- Andrea Mora de Marco Novellino
Visualizações232Abstract
Objective:
We aimed to compare the efficacy and safety of letrozole and clomiphene versus letrozole alone for ovulation induction in patients with Polycystic Ovary Syndrome (PCOS).
Data Sources:
We systematically searched EMBASE, PubMed, and Cochrane databases on October 31, 2024.
Study selection:
We included studies of women with PCOS treated with a combination of clomiphene and letrozole or letrozole alone to induce ovulation that reported any of the outcomes of interest, namely rate of mature follicles and ovulation, ovulation, pregnancy, miscarriages, endometrial thickness, and number of mature follicles.
Data collection:
We pooled odds ratios (OR) and mean difference (MD) with 95% confidence intervals (CI) using a random effects model using R statistical software, version 4.2.1. Heterogeneity was assessed with I statistics, and a random effects model was used.
Data Synthesis:
Four RCTs and two observational studies comprising 592 patients were included. Combined therapy was associated with a higher rate of a mature follicle (OR 2.74; 95% CI 1.72-4.37; p< 0.001; I=0%) and ovulation (OR 2.55; 95% CI 1.57-4.12; p< 0.001; I=35.9%). The number of mature follicles, number of pregnancies, thickness of endometrial lining, and the incidence of adverse events, including headache, abdominal bloating, fatigue, back pain, breast discomfort, and night sweats, were similar between groups.
Conclusion:
In women with anovulatory infertility secondary to PCOS, letrozole and clomiphene citrate combined therapy was associated with improved mature follicle and ovulation rates, with a similar safety profile compared to letrozole alone. However, no significant impact was observed on pregnancy rates.
Palavras-chave: ClomipheneInfertility, femaleLetrozoleOvulationOvulation InductionPolycystic ovary syndromeVer maisThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
- Karine Eskandar
-
Artigo de Revisão18/03/2025
Efficacy of vitamin C supplementation during pregnancy in the prevention of preterm birth: a systematic review and meta-analysis
- Ana Gabriela Alves Pereira ,
- Gabriela Oliveira Gonçalves Molino ,
- Ana Clara Felix de Farias Santos ,
- Maírla Marina Ferreira Dias ,
- Nicole dos Santos Pimenta , [ ... ],
- Pedro Henrique Costa Matos da Silva
Resumo
Artigo de RevisãoEfficacy of vitamin C supplementation during pregnancy in the prevention of preterm birth: a systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo1
- Ana Gabriela Alves Pereira ,
- Gabriela Oliveira Gonçalves Molino ,
- Ana Clara Felix de Farias Santos ,
- Maírla Marina Ferreira Dias ,
- Nicole dos Santos Pimenta ,
- Pedro Henrique Costa Matos da Silva
Visualizações209Abstract
Objective:
Preterm birth is a leading global cause of neonatal mortality and morbidity, with oxidative stress playing a role in its pathogenesis. Vitamin C, a powerful antioxidant, may help reduce this risk. This study assessed the effectiveness of vitamin C supplementation, both alone and with vitamin E, in preventing preterm birth compared to a placebo.
Data source:
Databases were systematically searched in PubMed, Cochrane and Embase in December 2023 and updated in May 2024.
Study Selection:
Included RCTs evaluated vitamin C's effect on preterm birth and related neonatal outcomes.
Data collect:
Statistical analyses used a random-effects model for pooled risk ratios (RR) and 95% confidence intervals (CI). Heterogeneity was assessed with the I² statistic.
Data synthesis:
Seventeen RCTs (21,567 patients) were analyzed. Vitamin C supplementation showed no significant difference compared to placebo for preterm birth (RR 1.04; 95% CI 0.96, 1.14). No significant differences were observed for neonatal death (RR 0.77; 95% CI 0.55, 1.08), NICU admission (RR 1.03; 95% CI 0.95, 1.13), preterm PROM (RR 1.04; 95% CI 0.63, 1.71), or birth weight (MD 52.41; 95% CI −19.65, 124.47). A slight decrease in gestational age was observed (MD 0.26; 95% CI −0.02, 0.55).
Conclusion:
Vitamin C supplementation alone or in combination with vitamin E does not significantly prevent preterm birth or improve related neonatal outcomes.
Palavras-chave: Ascorbic acidFetal membranes, premature ruptureGestational ageIntensive care units, neonatalPregnancyPremature birthVitamin C supplementationVitamin EVer maisVisualizações209This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Resumo
Artigo de RevisãoEfficacy of vitamin C supplementation during pregnancy in the prevention of preterm birth: a systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo1
- Ana Gabriela Alves Pereira ,
- Gabriela Oliveira Gonçalves Molino ,
- Ana Clara Felix de Farias Santos ,
- Maírla Marina Ferreira Dias ,
- Nicole dos Santos Pimenta ,
- Pedro Henrique Costa Matos da Silva
Visualizações209Abstract
Objective:
Preterm birth is a leading global cause of neonatal mortality and morbidity, with oxidative stress playing a role in its pathogenesis. Vitamin C, a powerful antioxidant, may help reduce this risk. This study assessed the effectiveness of vitamin C supplementation, both alone and with vitamin E, in preventing preterm birth compared to a placebo.
Data source:
Databases were systematically searched in PubMed, Cochrane and Embase in December 2023 and updated in May 2024.
Study Selection:
Included RCTs evaluated vitamin C's effect on preterm birth and related neonatal outcomes.
Data collect:
Statistical analyses used a random-effects model for pooled risk ratios (RR) and 95% confidence intervals (CI). Heterogeneity was assessed with the I² statistic.
Data synthesis:
Seventeen RCTs (21,567 patients) were analyzed. Vitamin C supplementation showed no significant difference compared to placebo for preterm birth (RR 1.04; 95% CI 0.96, 1.14). No significant differences were observed for neonatal death (RR 0.77; 95% CI 0.55, 1.08), NICU admission (RR 1.03; 95% CI 0.95, 1.13), preterm PROM (RR 1.04; 95% CI 0.63, 1.71), or birth weight (MD 52.41; 95% CI −19.65, 124.47). A slight decrease in gestational age was observed (MD 0.26; 95% CI −0.02, 0.55).
Conclusion:
Vitamin C supplementation alone or in combination with vitamin E does not significantly prevent preterm birth or improve related neonatal outcomes.
Palavras-chave: Ascorbic acidFetal membranes, premature ruptureGestational ageIntensive care units, neonatalPregnancyPremature birthVitamin C supplementationVitamin EVer maisThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
- Ana Gabriela Alves Pereira
-
Artigo de Revisão18/03/2025
Clinical repercussions of statin use during pregnancy: a review of the literature
- Joan Lins Serafim ,
- Pedro Lucas Santos de Menezes Teles ,
- Amanda Katharinne Souza Lima ,
- Jéssica dos Santos Coelho ,
- Paloma Luna Maranhão Conrado , [ ... ],
- George Alessandro Maranhão Conrado
Resumo
Artigo de RevisãoClinical repercussions of statin use during pregnancy: a review of the literature
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo2
- Joan Lins Serafim ,
- Pedro Lucas Santos de Menezes Teles ,
- Amanda Katharinne Souza Lima ,
- Jéssica dos Santos Coelho ,
- Paloma Luna Maranhão Conrado ,
- Valda Lúcia Moreira Luna ,
- Pauliana Valéria Machado Galvão ,
- George Alessandro Maranhão Conrado
Visualizações205Abstract
Statins are the most widely used pharmacological class for treating hyperlipidemia, although they are contraindicated during pregnancy. This study aims to demonstrate the clinical effects of statins in pregnant women through an interactive review. Fifteen original articles were selected, in English or Portuguese, within of five years. Statins have not been associated with the development of fetal malformations and their use may be useful in preventing unfavorable cardiovascular outcomes, with the potential to reduce oxidative stress and angiogenic dysfunction. However, the use of statins to prevent pre-eclampsia in humans has not been properly clarified and further studies are needed. Pravastatin is considered safer than statins for use during pregnancy.
Palavras-chave: Antihypertensive agentsHydroxymethylglutaryl-CoA reductase inhibitorsPravastatinPre-eclampsiaPregnancyPregnant womanVer maisVisualizações205This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Resumo
Artigo de RevisãoClinical repercussions of statin use during pregnancy: a review of the literature
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo2
- Joan Lins Serafim ,
- Pedro Lucas Santos de Menezes Teles ,
- Amanda Katharinne Souza Lima ,
- Jéssica dos Santos Coelho ,
- Paloma Luna Maranhão Conrado ,
- Valda Lúcia Moreira Luna ,
- Pauliana Valéria Machado Galvão ,
- George Alessandro Maranhão Conrado
Visualizações205Abstract
Statins are the most widely used pharmacological class for treating hyperlipidemia, although they are contraindicated during pregnancy. This study aims to demonstrate the clinical effects of statins in pregnant women through an interactive review. Fifteen original articles were selected, in English or Portuguese, within of five years. Statins have not been associated with the development of fetal malformations and their use may be useful in preventing unfavorable cardiovascular outcomes, with the potential to reduce oxidative stress and angiogenic dysfunction. However, the use of statins to prevent pre-eclampsia in humans has not been properly clarified and further studies are needed. Pravastatin is considered safer than statins for use during pregnancy.
Palavras-chave: Antihypertensive agentsHydroxymethylglutaryl-CoA reductase inhibitorsPravastatinPre-eclampsiaPregnancyPregnant womanVer maisThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
- Joan Lins Serafim
-
Artigo de Revisão18/03/2025
Low-level laser therapy for nipple trauma and pain during breastfeeding: systematic review and meta-analysis
- Maria Victória Candida Gaitero ,
- Ticiana Aparecida Alves de Mira ,
- Edna Jéssica Lima Gondim ,
- Simony Lira do Nascimento ,
- Fernanda Garanhani Surita
Resumo
Artigo de RevisãoLow-level laser therapy for nipple trauma and pain during breastfeeding: systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo3
- Maria Victória Candida Gaitero ,
- Ticiana Aparecida Alves de Mira ,
- Edna Jéssica Lima Gondim ,
- Simony Lira do Nascimento ,
- Fernanda Garanhani Surita
Visualizações254Abstract
Objective:
This study aimed to investigate the effect of low-level laser therapy (LLLT) on nipple trauma and pain during breastfeeding through a systematic review with a meta-analysis of selected studies.
Source of the data:
A thorough search was conducted on March 22, 2022, using the databases PubMed, SciELO, LILACS, PEDro, CINAHL, EMBASE, ScienceDirect, Scopus, Google Scholar, MEDLINE, the Cochrane Library, Clinical Trials, Web of Science, TRIP, DARE, and ProQuest. The search terms included various combinations of low-level laser therapy, nipple pain, nipple trauma, and breastfeeding.
Studies selection:
Out of 107 articles identified, only three controlled and randomized clinical trials was included. The extracted data encompassed breast and trauma characteristics, treatment types, outcomes (pain and healing process), evaluation tools, LLLT usage, laser brand, and parameters.
Data collection:
Data extraction was performed using RAYYAN for systematic reviews. The risk of bias in the studies was evaluated.
Data synthesis:
Pain was measured using the visual analog scale (VAS). The included studies did not use validated tools for assessing physical conditions. All studies employed LLLT with a 660-nm wavelength, though there were variations in equipment power, energy dose, and application methods. The meta-analysis revealed an average difference of −0.60 points (95% CI: −1.52 to 0.31) in the VAS pain scores between the LLLT and control groups. No heterogeneity was observed among the studies (I2=0%), indicating no significant difference in pain relief between LLLT (red light) and control groups.
Conclusion:
LLLT may offer a promising option for managing breastfeeding-related complications, though further research is required.
Palavras-chave: Breast feedingLaser therapyLow level light therapyLow-level laserNipple painNipple traumaNipplesVer maisVisualizações254This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Resumo
Artigo de RevisãoLow-level laser therapy for nipple trauma and pain during breastfeeding: systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo3
- Maria Victória Candida Gaitero ,
- Ticiana Aparecida Alves de Mira ,
- Edna Jéssica Lima Gondim ,
- Simony Lira do Nascimento ,
- Fernanda Garanhani Surita
Visualizações254Abstract
Objective:
This study aimed to investigate the effect of low-level laser therapy (LLLT) on nipple trauma and pain during breastfeeding through a systematic review with a meta-analysis of selected studies.
Source of the data:
A thorough search was conducted on March 22, 2022, using the databases PubMed, SciELO, LILACS, PEDro, CINAHL, EMBASE, ScienceDirect, Scopus, Google Scholar, MEDLINE, the Cochrane Library, Clinical Trials, Web of Science, TRIP, DARE, and ProQuest. The search terms included various combinations of low-level laser therapy, nipple pain, nipple trauma, and breastfeeding.
Studies selection:
Out of 107 articles identified, only three controlled and randomized clinical trials was included. The extracted data encompassed breast and trauma characteristics, treatment types, outcomes (pain and healing process), evaluation tools, LLLT usage, laser brand, and parameters.
Data collection:
Data extraction was performed using RAYYAN for systematic reviews. The risk of bias in the studies was evaluated.
Data synthesis:
Pain was measured using the visual analog scale (VAS). The included studies did not use validated tools for assessing physical conditions. All studies employed LLLT with a 660-nm wavelength, though there were variations in equipment power, energy dose, and application methods. The meta-analysis revealed an average difference of −0.60 points (95% CI: −1.52 to 0.31) in the VAS pain scores between the LLLT and control groups. No heterogeneity was observed among the studies (I2=0%), indicating no significant difference in pain relief between LLLT (red light) and control groups.
Conclusion:
LLLT may offer a promising option for managing breastfeeding-related complications, though further research is required.
Palavras-chave: Breast feedingLaser therapyLow level light therapyLow-level laserNipple painNipple traumaNipplesVer maisThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
- Maria Victória Candida Gaitero
-
Artigo de Revisão18/03/2025
Short cervix and use of cervical pessary for preventing preterm birth in singleton and twin pregnancies: a systematic review and meta-analysis
- Ana Clara Felix de Farias Santos ,
- Nicole dos Santos Pimenta ,
- Ana Gabriela Alves Pereira ,
- Gabriela Oliveira Gonçalves Molino ,
- Maírla Marina Ferreira Dias , [ ... ],
- Pedro Henrique Costa Matos da Silva
Resumo
Artigo de RevisãoShort cervix and use of cervical pessary for preventing preterm birth in singleton and twin pregnancies: a systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo10
- Ana Clara Felix de Farias Santos ,
- Nicole dos Santos Pimenta ,
- Ana Gabriela Alves Pereira ,
- Gabriela Oliveira Gonçalves Molino ,
- Maírla Marina Ferreira Dias ,
- Pedro Henrique Costa Matos da Silva
Visualizações242Ver maisAbstract
Objective:
Preterm birth remains a significant contributor to neonatal morbidity and mortality. The use of cervical pessaries as an intervention for preventing preterm delivery in women with a short cervix has been a subject of interest. We evaluated the effectiveness of cervical pessary compared to standard care in preventing preterm delivery in women with a short cervix.
Data source:
Databases were systematically searched in PubMed, Cochrane, and Embase databases in December 2023.
Study selection:
Randomized clinical trials with the outcomes of interest were included.
Data collect:
We computed risk ratios for binary endpoints, with 95% confidence intervals. Heterogeneity was assessed using I2 statistics. Data were analyzed using R software (version 4.3.0). The primary outcomes of interest were preterm delivery before 37 weeks, and preterm delivery before 34 weeks.
Data synthesis:
Seventeen studies with 5,704 patients were included. The use of cervical pessary was associated with a decreased risk of preterm delivery before 37 (RR 0.88; 95% CI 0.81-0.96) and 34 weeks (RR 0.79; 95% CI 0.63-0.99) of gestation in twin pregnancies as compared to standard care without progesterone. There were no significant differences in preterm delivery in singleton pregnancy, neonatal outcomes, preterm premature rupture of the membranes or chorioamnionitis.
Conclusion:
The use of cervical pessary was associated with a significant reduction in preterm delivery at 34 and 37 weeks of gestation in twin pregnancies among patients with a short cervix compared to no treatment. No significant difference was found in singleton pregnancies or maternal outcomes.
Visualizações242This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Resumo
Artigo de RevisãoShort cervix and use of cervical pessary for preventing preterm birth in singleton and twin pregnancies: a systematic review and meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2025;47:e-rbgo10
- Ana Clara Felix de Farias Santos ,
- Nicole dos Santos Pimenta ,
- Ana Gabriela Alves Pereira ,
- Gabriela Oliveira Gonçalves Molino ,
- Maírla Marina Ferreira Dias ,
- Pedro Henrique Costa Matos da Silva
Visualizações242Ver maisAbstract
Objective:
Preterm birth remains a significant contributor to neonatal morbidity and mortality. The use of cervical pessaries as an intervention for preventing preterm delivery in women with a short cervix has been a subject of interest. We evaluated the effectiveness of cervical pessary compared to standard care in preventing preterm delivery in women with a short cervix.
Data source:
Databases were systematically searched in PubMed, Cochrane, and Embase databases in December 2023.
Study selection:
Randomized clinical trials with the outcomes of interest were included.
Data collect:
We computed risk ratios for binary endpoints, with 95% confidence intervals. Heterogeneity was assessed using I2 statistics. Data were analyzed using R software (version 4.3.0). The primary outcomes of interest were preterm delivery before 37 weeks, and preterm delivery before 34 weeks.
Data synthesis:
Seventeen studies with 5,704 patients were included. The use of cervical pessary was associated with a decreased risk of preterm delivery before 37 (RR 0.88; 95% CI 0.81-0.96) and 34 weeks (RR 0.79; 95% CI 0.63-0.99) of gestation in twin pregnancies as compared to standard care without progesterone. There were no significant differences in preterm delivery in singleton pregnancy, neonatal outcomes, preterm premature rupture of the membranes or chorioamnionitis.
Conclusion:
The use of cervical pessary was associated with a significant reduction in preterm delivery at 34 and 37 weeks of gestation in twin pregnancies among patients with a short cervix compared to no treatment. No significant difference was found in singleton pregnancies or maternal outcomes.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
- Ana Clara Felix de Farias Santos
-
Artigo de Revisão04/12/2024
Zuranolone for postpartum depression: a systematic review and meta-analysis of two randomized studies
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo79
Resumo
Artigo de RevisãoZuranolone for postpartum depression: a systematic review and meta-analysis of two randomized studies
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo79
Visualizações350Ver maisAbstract
Objective:
To evaluate the maternal outcomes in women with postpartum depression using zuranolone, the first oral medication indicated to treat postpartum depression.
Methods:
We conducted a systematic search in September 2023, on Pubmed, Embase and Cochrane Trials. We included randomized controlled trials comparing the effectiveness and safety of zuranolone versus placebo in women with postpartum depression. No time or language restrictions were applied. 297 results were retrieved, of which 11 papers were selected and fully reviewed by two authors. Review Manager 5 was used for statistical analysis and Cochrane Risk-of-bias tool for randomized trials was applied for quality assessment.
Results:
We included 2 studies, with 346 women, of whom 174 (50.2%) were treated with zuranolone. Zuranolone was significantly associated to an improvement of Clinical Global Impression response rate; Hamilton Depression Rating Scale 15 days and 45-day remission, 3-day, 15-day, and 45-day symptom remission, and reduction in the dose of antidepressants. As for safety outcomes, it was noticed that zuranolone increases sedation risk, which can be dose related. No significant differences were found for other adverse events.
Conclusion:
These findings suggest that zuranolone might present a safe and effective medication for out-of-hospital treatment of PPD. Sedation effects need to be further assessed.
Visualizações350This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Resumo
Artigo de RevisãoZuranolone for postpartum depression: a systematic review and meta-analysis of two randomized studies
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgo79
Visualizações350Ver maisAbstract
Objective:
To evaluate the maternal outcomes in women with postpartum depression using zuranolone, the first oral medication indicated to treat postpartum depression.
Methods:
We conducted a systematic search in September 2023, on Pubmed, Embase and Cochrane Trials. We included randomized controlled trials comparing the effectiveness and safety of zuranolone versus placebo in women with postpartum depression. No time or language restrictions were applied. 297 results were retrieved, of which 11 papers were selected and fully reviewed by two authors. Review Manager 5 was used for statistical analysis and Cochrane Risk-of-bias tool for randomized trials was applied for quality assessment.
Results:
We included 2 studies, with 346 women, of whom 174 (50.2%) were treated with zuranolone. Zuranolone was significantly associated to an improvement of Clinical Global Impression response rate; Hamilton Depression Rating Scale 15 days and 45-day remission, 3-day, 15-day, and 45-day symptom remission, and reduction in the dose of antidepressants. As for safety outcomes, it was noticed that zuranolone increases sedation risk, which can be dose related. No significant differences were found for other adverse events.
Conclusion:
These findings suggest that zuranolone might present a safe and effective medication for out-of-hospital treatment of PPD. Sedation effects need to be further assessed.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Artigo de Revisão Archives - Revista Brasileira de Ginecologia e Obstetrícia
